Quality control gone wrong: Mitochondria, lysosomal storage disorders and neurodegeneration

British Journal of Pharmacology

Volumn 171, Issue 8, 2014, Pages 1958-1972

  Osellame, L D ^a   Duchen, M R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

autophagy; Gaucher disease; lysosomal storage disorders; lysosome; mitochondria; neurodegeneration; Parkinson's disease; ubiquitin proteasome system

Indexed keywords

ALPHA SYNUCLEIN; GLUCOSYLCERAMIDASE; PROTEASOME; REACTIVE OXYGEN METABOLITE; UBIQUITIN;

AUTOPHAGY; CHAPERONE MEDIATED AUTOPHAGY; DISEASE ASSOCIATION; ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION; GAUCHER DISEASE; GLYCOLYSIS; GM1 GANGLIOSIDOSIS; HUMAN; LEWY BODY; LYSOSOME STORAGE DISEASE; MACROAUTOPHAGY; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MITOPHAGY; MUCOLIPIDOSIS; MULTIPLE SULFATASE DEFICIENCY; NERVE CELL NECROSIS; NERVE DEGENERATION; NEURONAL CEROID LIPOFUSCINOSIS; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN HOMEOSTASIS; REVIEW; UBIQUITINATION; BIOLOGICAL MODEL; COMPLICATION; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; PATHOPHYSIOLOGY; PHYSIOLOGY;

AUTOPHAGY; GAUCHER DISEASE; HUMANS; LYSOSOMAL STORAGE DISEASES; MITOCHONDRIAL DEGRADATION; MITOCHONDRIAL DISEASES; MODELS, BIOLOGICAL; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE;

EID: 84897454469     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12453     Document Type: Review

References (182)

1. Abbas N, Lucking CB, Ricard S, Durr A, Bonifati V, De Michele G, et al. (1999). A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Hum Mol Genet 8: 567-574.
2. Abou-Sleiman PM, Muqit MM, Wood NW, (2006). Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 7: 207-219.
3. Agarraberes FA, Dice JF, (2001). Protein translocation across membranes. Biochim Biophys Acta 1513: 1-24.
4. Agarraberes FA, Terlecky SR, Dice JF, (1997). An intralysosomal hsp70 is required for a selective pathway of lysosomal protein degradation. J Cell Biol 137: 825-834.
5. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R, (2004). Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 351: 1972-1977.
6. Altarescu G, Sun M, Moore DF, Smith JA, Wiggs EA, Solomon BI, et al. (2002). The neurogenetics of mucolipidosis type IV. Neurology 59: 306-313.
7. Andersson SG, Zomorodipour A, Andersson JO, Sicheritz-Ponten T, Alsmark UC, Podowski RM, et al. (1998). The genome sequence of Rickettsia prowazekii and the origin of mitochondria. Nature 396: 133-140.
8. Austin JH, (1973). Studies in metachromatic leukodystrophy. XII Multiple sulfatase deficiency. Arch Neurol 28: 258-264.
9. Axe EL, Walker SA, Manifava M, Chandra P, Roderick HL, Habermann A, et al. (2008). Autophagosome formation from membrane compartments enriched in phosphatidylinositol 3-phosphate and dynamically connected to the endoplasmic reticulum. J Cell Biol 182: 685-701.
10. Bach G, Desnick RJ, (1988). Lysosomal accumulation of phospholipids in mucolipidosis IV cultured fibroblasts. Enzyme 40: 40-44.
11. Bach G, Webb MB, Bargal R, Zeigler M, Ekstein J, (2005). The frequency of mucolipidosis type IV in the Ashkenazi Jewish population and the identification of 3 novel MCOLN1 mutations. Hum Mutat 26: 397-402.
12. Bargal R, Bach G, (1989). Phosphatidylcholine storage in mucolipidosis IV. Clin Chim Acta 181: 167-174.
13. Bargal R, Avidan N, Olender T, Ben Asher E, Zeigler M, Raas-Rothschild A, et al. (2001). Mucolipidosis type IV: novel MCOLN1 mutations in Jewish and non-Jewish patients and the frequency of the disease in the Ashkenazi Jewish population. Hum Mutat 17: 397-402.
14. Beasley SA, Hristova VA, Shaw GS, (2007). Structure of the Parkin in-between-ring domain provides insights for E3-ligase dysfunction in autosomal recessive Parkinson's disease. Proc Natl Acad Sci U S A 104: 3095-3100.
15. Bence NF, Sampat RM, Kopito RR, (2001). Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292: 1552-1555.
16. Bernales S, McDonald KL, Walter P, (2006). Autophagy counterbalances endoplasmic reticulum expansion during the unfolded protein response. PLoS Biol 4: e423.
17. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT, (2000). Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3: 1301-1306.
18. Beutler E, Gelbart T, (1993). Gaucher disease mutations in non-Jewish patients. Br J Haematol 85: 401-405.
19. Beutler E, Nguyen NJ, Henneberger MW, Smolec JM, McPherson RA, West C, et al. (1993). Gaucher disease: gene frequencies in the Ashkenazi Jewish population. Am J Hum Genet 52: 85-88.
20. Bjorkoy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, et al. (2005). p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol 171: 603-614.
21. Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, et al. (2008). Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. J Neurosci 28: 6926-6937.
22. Bolanos JP, Almeida A, Moncada S, (2010). Glycolysis: a bioenergetic or a survival pathway? Trends Biochem Sci 35: 145-149.
23. Brady RO, Kanfer J, Shapiro D, (1965). The metabolism of glucocerebrosides. I. Purification and properties of a glucocerebroside-cleaving enzyme from spleen tissue. J Biol Chem 240: 39-43.
24. Brunetti-Pierri N, Scaglia F, (2008). GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects. Mol Genet Metab 94: 391-396.
25. Cao Y, Espinola JA, Fossale E, Massey AC, Cuervo AM, MacDonald ME, et al. (2006). Autophagy is disrupted in a knock-in mouse model of juvenile neuronal ceroid lipofuscinosis. J Biol Chem 281: 20483-20493.
26. Cesen MH, Pegan K, Spes A, Turk B, (2012). Lysosomal pathways to cell death and their therapeutic applications. Exp Cell Res 318: 1245-1251.
27. Chan NC, Salazar AM, Pham AH, Sweredoski MJ, Kolawa NJ, Graham RL, et al. (2011). Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy. Hum Mol Genet 20: 1726-1737.
28. Chance B, Sies H, Boveris A, (1979). Hydroperoxide metabolism in mammalian organs. Physiol Rev 59: 527-605.
29. Chen Y, Dorn GW, 2nd, (2013). PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. Science 340: 471-475.
30. Chiang HL, Dice JF, (1988). Peptide sequences that target proteins for enhanced degradation during serum withdrawal. J Biol Chem 263: 6797-6805.
31. Chiang HL, Terlecky SR, Plant CP, Dice JF, (1989). A role for a 70-kilodalton heat shock protein in lysosomal degradation of intracellular proteins. Science 246: 382-385.
32. Chieregatti E, Meldolesi J, (2005). Regulated exocytosis: new organelles for non-secretory purposes. Nat Rev Mol Cell Biol 6: 181-187.
33. Churchill GC, Okada Y, Thomas JM, Genazzani AA, Patel S, Galione A, (2002). NAADP mobilizes Ca(2+) from reserve granules, lysosome-related organelles, in sea urchin eggs. Cell 111: 703-708.
34. Cleeter MW, Chau KY, Gluck C, Mehta A, Hughes DA, Duchen M, et al. (2013). Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem Int 62: 1-7.
35. Cosma MP, Pepe S, Annunziata I, Newbold RF, Grompe M, Parenti G, et al. (2003). The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell 113: 445-456.
36. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D, (2004). Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305: 1292-1295.
37. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D, (2006). Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127: 59-69.
38. Dahlmann B, Kopp F, Kuehn L, Reinauer H, Schwenen M, (1986). Studies on the multicatalytic proteinase from rat skeletal muscle. Biomed Biochim Acta 45: 1493-1501.
39. Dawson G, Kilkus J, Siakotos AN, Singh I, (1996). Mitochondrial abnormalities in CLN2 and CLN3 forms of Batten disease. Mol Chem Neuropathol 29: 227-235.
40. De Duve C, Pressman BC, Gianetto R, Wattiaux R, Appelmans F, (1955). Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. Biochem J 60: 604-617.
41. Deas E, Plun-Favreau H, Gandhi S, Desmond H, Kjaer S, Loh SH, et al. (2011). PINK1 cleavage at position A103 by the mitochondrial protease PARL. Hum Mol Genet 20: 867-879.
42. Dehay B, Bove J, Rodriguez-Muela N, Perier C, Recasens A, Boya P, et al. (2010). Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci 30: 12535-12544.
43. Dehay B, Martinez-Vicente M, Caldwell GA, Caldwell KA, Yue Z, Cookson MR, et al. (2013). Lysosomal impairment in Parkinson's disease. Mov Disord 28: 725-732.
44. DePaolo J, Goker-Alpan O, Samaddar T, Lopez G, Sidransky E, (2009). The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism. Mov Disord 24: 1571-1578.
45. Deshaies RJ, Joazeiro CA, (2009). RING domain E3 ubiquitin ligases. Annu Rev Biochem 78: 399-434.
46. Dice JF, (2007). Chaperone-mediated autophagy. Autophagy 3: 295-299.
47. Dierks T, Schmidt B, Borissenko LV, Peng J, Preusser A, Mariappan M, et al. (2003). Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme. Cell 113: 435-444.
48. Duchen MR, (1999). Contributions of mitochondria to animal physiology: from homeostatic sensor to calcium signalling and cell death. J Physiol 516 (Pt 1): 1-17.
49. Duchen MR, (2000). Mitochondria and calcium: from cell signalling to cell death. J Physiol 529 (Pt 1): 57-68.
50. Dunn WA, Jr, Cregg JM, Kiel JA, van der Klei IJ, Oku M, Sakai Y, et al. (2005). Pexophagy: the selective autophagy of peroxisomes. Autophagy 1: 75-83.
51. Ebrahimi-Fakhari D, Cantuti-Castelvetri I, Fan Z, Rockenstein E, Masliah E, Hyman BT, et al. (2011). Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of alpha-synuclein. J Neurosci 31: 14508-14520.
52. Elsasser S, Finley D, (2005). Delivery of ubiquitinated substrates to protein-unfolding machines. Nat Cell Biol 7: 742-749.
53. Enquist IB, Nilsson E, Ooka A, Mansson JE, Olsson K, Ehinger M, et al. (2006). Effective cell and gene therapy in a murine model of Gaucher disease. Proc Natl Acad Sci U S A 103: 13819-13824.
54. Fader CM, Sanchez DG, Mestre MB, Colombo MI, (2009). TI-VAMP/VAMP7 and VAMP3/cellubrevin: two v-SNARE proteins involved in specific steps of the autophagy/multivesicular body pathways. Biochim Biophys Acta 1793: 1901-1916.
55. Fares H, Greenwald I, (2001). Regulation of endocytosis by CUP-5, the Caenorhabditis elegans mucolipin-1 homolog. Nat Genet 28: 64-68.
56. Fleming A, Noda T, Yoshimori T, Rubinsztein DC, (2011). Chemical modulators of autophagy as biological probes and potential therapeutics. Nat Chem Biol 7: 9-17.
57. Funderburk SF, Wang QJ, Yue Z, (2010). The Beclin 1-VPS34 complex-at the crossroads of autophagy and beyond. Trends Cell Biol 20: 355-362.
58. Futerman AH, van Meer G, (2004). The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol 5: 554-565.
59. Gandhi S, Wood-Kaczmar A, Yao Z, Plun-Favreau H, Deas E, Klupsch K, et al. (2009). PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol Cell 33: 627-638.
60. Gegg ME, Cooper JM, Chau KY, Rojo M, Schapira AH, Taanman JW, (2010). Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. Hum Mol Genet 19: 4861-4870.
61. Gegg ME, Burke D, Heales SJ, Cooper JM, Hardy J, Wood NW, et al. (2012). Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol 72: 455-463.
62. Geisler S, Holmstrom KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ, et al. (2010). PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol 12: 119-131.
63. Grabowski GA, (2008). Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 372: 1263-1271.
64. Green DR, Reed JC, (1998). Mitochondria and apoptosis. Science 281: 1309-1312.
65. Greene AW, Grenier K, Aguileta MA, Muise S, Farazifard R, Haque ME, et al. (2012). Mitochondrial processing peptidase regulates PINK1 processing, import and Parkin recruitment. EMBO Rep 13: 378-385.
66. Hailey DW, Rambold AS, Satpute-Krishnan P, Mitra K, Sougrat R, Kim PK, et al. (2010). Mitochondria supply membranes for autophagosome biogenesis during starvation. Cell 141: 656-667.
67. Hall NA, Lake BD, Dewji NN, Patrick AD, (1991). Lysosomal storage of subunit c of mitochondrial ATP synthase in Batten's disease (ceroid- lipofuscinosis). Biochem J 275 (Pt 1): 269-272.
68. Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R, et al. (2006). Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441: 885-889.
69. Heinemeyer W, Fischer M, Krimmer T, Stachon U, Wolf DH, (1997). The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing. J Biol Chem 272: 25200-25209.
70. Herrero-Mendez A, Almeida A, Fernandez E, Maestre C, Moncada S, Bolanos JP, (2009). The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. Nat Cell Biol 11: 747-752.
71. Hershko A, Heller H, Elias S, Ciechanover A, (1983). Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J Biol Chem 258: 8206-8214.
72. Hruska KS, LaMarca ME, Scott CR, Sidransky E, (2008). Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 29: 567-583.
73. James AM, Smith RA, Murphy MP, (2004). Antioxidant and prooxidant properties of mitochondrial coenzyme Q. Arch Biochem Biophys 423: 47-56.
74. Jennings JJ, Jr, Zhu JH, Rbaibi Y, Luo X, Chu CT, Kiselyov K, (2006). Mitochondrial aberrations in mucolipidosis Type IV. J Biol Chem 281: 39041-39050.
75. Jin SM, Lazarou M, Wang C, Kane LA, Narendra DP, Youle RJ, (2010). Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. J Cell Biol 191: 933-942.
76. Kilpatrick BS, Eden ER, Schapira AH, Futter CE, Patel S, (2013). Direct mobilisation of lysosomal Ca2+ triggers complex Ca2+ signals. J Cell Sci 126: 60-66.
77. Kim I, Lemasters JJ, (2011). Mitophagy selectively degrades individual damaged mitochondria after photoirradiation. Antioxid Redox Signal 14: 1919-1928.
78. Kim I, Rodriguez-Enriquez S, Lemasters JJ, (2007). Selective degradation of mitochondria by mitophagy. Arch Biochem Biophys 462: 245-253.
79. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605-608.
80. Klionsky DJ, Emr SD, (2000). Autophagy as a regulated pathway of cellular degradation. Science 290: 1717-1721.
81. Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, et al. (2006). Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 441: 880-884.
82. Korolchuk VI, Mansilla A, Menzies FM, Rubinsztein DC, (2009). Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates. Mol Cell 33: 517-527.
83. Korolchuk VI, Menzies FM, Rubinsztein DC, (2010). Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. FEBS Lett 584: 1393-1398.
84. Kraft C, Deplazes A, Sohrmann M, Peter M, (2008). Mature ribosomes are selectively degraded upon starvation by an autophagy pathway requiring the Ubp3p/Bre5p ubiquitin protease. Nat Cell Biol 10: 602-610.
85. Kruman II, Mattson MP, (1999). Pivotal role of mitochondrial calcium uptake in neural cell apoptosis and necrosis. J Neurochem 72: 529-540.
86. Kuusisto E, Salminen A, Alafuzoff I, (2001). Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. Neuroreport 12: 2085-2090.
87. Kuusisto E, Salminen A, Alafuzoff I, (2002). Early accumulation of p62 in neurofibrillary tangles in Alzheimer's disease: possible role in tangle formation. Neuropathol Appl Neurobiol 28: 228-237.
88. LaPlante JM, Ye CP, Quinn SJ, Goldin E, Brown EM, Slaugenhaupt SA, et al. (2004). Functional links between mucolipin-1 and Ca2+-dependent membrane trafficking in mucolipidosis IV. Biochem Biophys Res Commun 322: 1384-1391.
89. Lazarou M, Jin SM, Kane LA, Youle RJ, (2012). Role of PINK1 binding to the TOM complex and alternate intracellular membranes in recruitment and activation of the E3 ligase parkin. Dev Cell 22: 320-333.
90. Lazarou M, Narendra DP, Jin SM, Tekle E, Banerjee S, Youle RJ, (2013). PINK1 drives Parkin self-association and HECT-like E3 activity upstream of mitochondrial binding. J Cell Biol 200: 163-172.
91. Lee J, Giordano S, Zhang J, (2012). Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochem J 441: 523-540.
92. Lemasters JJ, Nieminen AL, Qian T, Trost LC, Elmore SP, Nishimura Y, et al. (1998). The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1366: 177-196.
93. Lesage S, Anheim M, Condroyer C, Pollak P, Durif F, Dupuits C, et al. (2011). Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum Mol Genet 20: 202-210.
94. Levine B, Klionsky DJ, (2004). Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 6: 463-477.
95. Levine B, Kroemer G, (2008). Autophagy in the pathogenesis of disease. Cell 132: 27-42.
96. Levinger L, Morl M, Florentz C, (2004). Mitochondrial tRNA 3′ end metabolism and human disease. Nucleic Acids Res 32: 5430-5441.
97. Lin MT, Beal MF, (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443: 787-795.
98. Liu Y, Fiskum G, Schubert D, (2002). Generation of reactive oxygen species by the mitochondrial electron transport chain. J Neurochem 80: 780-787.
99. Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R, (1995). Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 268: 533-539.
100. Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, et al. (2000). Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 342: 1560-1567.
101. McBride HM, Neuspiel M, Wasiak S, (2006). Mitochondria: more than just a powerhouse. Curr Biol 16: R551-R560.
102. Mach L, (2002). Biosynthesis of lysosomal proteinases in health and disease. Biol Chem 383: 751-756.
103. McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P, (2001). Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci 2: 589-594.
104. Mancini GM, Havelaar AC, Verheijen FW, (2000). Lysosomal transport disorders. J Inherit Metab Dis 23: 278-292.
105. Manzoni C, Lewis PA, (2013). Dysfunction of the autophagy/lysosomal degradation pathway is a shared feature of the genetic synucleinopathies. FASEB J 27: 3424-3429.
106. Martinez-Vicente M, Cuervo AM, (2007). Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol 6: 352-361.
107. Mata IF, Samii A, Schneer SH, Roberts JW, Griffith A, Leis BC, et al. (2008). Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch Neurol 65: 379-382.
108. Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, et al. (2011). Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146: 37-52.
109. Mecocci P, MacGarvey U, Beal MF, (1994). Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 36: 747-751.
110. Meikle PJ, Hopwood JJ, Clague AE, Carey WF, (1999). Prevalence of lysosomal storage disorders. JAMA 281: 249-254.
111. Mitchell P, (1961). Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism. Nature 191: 144-148.
112. Mitchell P, Moyle J, (1967). Chemiosmotic hypothesis of oxidative phosphorylation. Nature 213: 137-139.
113. Mitsui J, Mizuta I, Toyoda A, Ashida R, Takahashi Y, Goto J, et al. (2009). Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol 66: 571-576.
114. Mullins C, Bonifacino JS, (2001). The molecular machinery for lysosome biogenesis. Bioessays 23: 333-343.
115. Murphy MP, Smith RA, (2007). Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 47: 629-656.
116. Nagaoka U, Kim K, Jana NR, Doi H, Maruyama M, Mitsui K, et al. (2004). Increased expression of p62 in expanded polyglutamine-expressing cells and its association with polyglutamine inclusions. J Neurochem 91: 57-68.
117. Nandi D, Tahiliani P, Kumar A, Chandu D, (2006). The ubiquitin-proteasome system. J Biosci 31: 137-155.
118. Narendra D, Tanaka A, Suen DF, Youle RJ, (2008). Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 183: 795-803.
119. Neudorfer O, Giladi N, Elstein D, Abrahamov A, Turezkite T, Aghai E, et al. (1996). Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 89: 691-694.
120. Neumann J, Bras J, Deas E, O'Sullivan SS, Parkkinen L, Lachmann RH, et al. (2009). Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 132: 1783-1794.
121. Okada S, O'Brien JS, (1968). Generalized gangliosidosis: beta-galactosidase deficiency. Science 160: 1002-1004.
122. Ong SB, Subrayan S, Lim SY, Yellon DM, Davidson SM, Hausenloy DJ, (2010). Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation 121: 2012-2022.
123. Osellame LD, Blacker TS, Duchen MR, (2012). Cellular and molecular mechanisms of mitochondrial function. Best Pract Res Clin Endocrinol Metab 26: 711-723.
124. Osellame LD, Rahim AA, Hargreaves IP, Gegg ME, Richard-Londt A, Brandner S, et al. (2013). Mitochondria and quality control defects in a mouse model of gaucher disease-links to Parkinson's disease. Cell Metab 17: 941-953.
125. Otomo T, Higaki K, Nanba E, Ozono K, Sakai N, (2009). Inhibition of autophagosome formation restores mitochondrial function in mucolipidosis II and III skin fibroblasts. Mol Genet Metab 98: 393-399.
126. de Pablo-Latorre R, Saide A, Polishhuck EV, Nusco E, Fraldi A, Ballabio A, (2012). Impaired parkin-mediated mitochondrial targeting to autophagosomes differentially contributes to tissue pathology in lysosomal storage diseases. Hum Mol Genet 21: 1770-1781.
127. Palmer DN, Fearnley IM, Walker JE, Hall NA, Lake BD, Wolfe LS, et al. (1992). Mitochondrial ATP synthase subunit c storage in the ceroid- lipofuscinoses (Batten disease). Am J Med Genet 42: 561-567.
128. Pan T, Kondo S, Le W, Jankovic J, (2008). The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 131: 1969-1978.
129. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, et al. (2002). Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 5: 731-736.
130. Park MK, Ashby MC, Erdemli G, Petersen OH, Tepikin AV, (2001). Perinuclear, perigranular and sub-plasmalemmal mitochondria have distinct functions in the regulation of cellular calcium transport. EMBO J 20: 1863-1874.
131. Pickart CM, Eddins MJ, (2004). Ubiquitin: structures, functions, mechanisms. Biochim Biophys Acta 1695: 55-72.
132. Poole AC, Thomas RE, Yu S, Vincow ES, Pallanck L, (2010). The mitochondrial fusion-promoting factor mitofusin is a substrate of the PINK1/parkin pathway. PLoS One 5: e10054.
133. Rahim AA, Wong AM, Howe SJ, Buckley SM, Acosta-Saltos AD, Elston KE, et al. (2009). Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors. Gene Ther 16: 509-520.
134. Rich P, (2003). Chemiosmotic coupling: the cost of living. Nature 421: 583.
135. Rodrigo-Brenni MC, Foster SA, Morgan DO, (2010). Catalysis of lysine 48-specific ubiquitin chain assembly by residues in E2 and ubiquitin. Mol Cell 39: 548-559.
136. Ron D, Walter P, (2007). Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8: 519-529.
137. Ron I, Horowitz M, (2005). ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum Mol Genet 14: 2387-2398.
138. Ross CA, Pickart CM, (2004). The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases. Trends Cell Biol 14: 703-711.
139. Ross JM, Stewart JB, Hagstrom E, Brene S, Mourier A, Coppotelli G, et al. (2013). Germline mitochondrial DNA mutations aggravate ageing and can impair brain development. Nature 501: 412-415. doi: 10.1038/nature12474.
140. Roze E, Paschke E, Lopez N, Eck T, Yoshida K, Maurel-Ollivier A, et al. (2005). Dystonia and parkinsonism in GM1 type 3 gangliosidosis. Mov Disord 20: 1366-1369.
141. Rubinsztein DC, (2006). The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443: 780-786.
142. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ, (2007). Potential therapeutic applications of autophagy. Nat Rev Drug Discov 6: 304-312.
143. Ryan MT, Hoogenraad NJ, (2007). Mitochondrial-nuclear communications. Annu Rev Biochem 76: 701-722.
144. Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM, (2010). Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 141: 290-303.
145. Sano R, Annunziata I, Patterson A, Moshiach S, Gomero E, Opferman J, et al. (2009). GM1-ganglioside accumulation at the mitochondria-associated ER membranes links ER stress to Ca(2+)-dependent mitochondrial apoptosis. Mol Cell 36: 500-511.
146. Santavuori P, (1988). Neuronal ceroid-lipofuscinoses in childhood. Brain Dev 10: 80-83.
147. Santorelli FM, Shanske S, Macaya A, DeVivo DC, DiMauro S, (1993). The mutation at nt 8993 of mitochondrial DNA is a common cause of Leigh's syndrome. Ann Neurol 34: 827-834.
148. Santos RX, Correia SC, Carvalho C, Cardoso S, Santos MS, Moreira PI, (2011). Mitophagy in neurodegeneration: an opportunity for therapy? Curr Drug Targets 12: 790-799.
149. Sarraf SA, Raman M, Guarani-Pereira V, Sowa ME, Huttlin EL, Gygi SP, et al. (2013). Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization. Nature 496: 372-376.
150. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD, (1990a). Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54: 823-827.
151. Schapira AH, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, et al. (1990b). Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 55: 2142-2145.
152. Schinzel AC, Takeuchi O, Huang Z, Fisher JK, Zhou Z, Rubens J, et al. (2005). Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc Natl Acad Sci U S A 102: 12005-12010.
153. Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR, Wooten MW, (2004). Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol 24: 8055-8068.
154. Seth RB, Sun L, Ea CK, Chen ZJ, (2005). Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 122: 669-682.
155. Settembre C, Fraldi A, Jahreiss L, Spampanato C, Venturi C, Medina D, et al. (2008a). A block of autophagy in lysosomal storage disorders. Hum Mol Genet 17: 119-129.
156. Settembre C, Fraldi A, Rubinsztein DC, Ballabio A, (2008b). Lysosomal storage diseases as disorders of autophagy. Autophagy 4: 113-114.
157. Settembre C, Fraldi A, Medina DL, Ballabio A, (2013). Signals from the lysosome: a control centre for cellular clearance and energy metabolism. Nat Rev Mol Cell Biol 14: 283-296.
158. Shachar T, Lo Bianco C, Recchia A, Wiessner C, Raas-Rothschild A, Futerman AH, (2011). Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond. Mov Disord 26: 1593-1604.
159. Sidransky E, (2005). Gaucher disease and parkinsonism. Mol Genet Metab 84: 302-304.
160. Sidransky E, Lopez G, (2012). The link between the GBA gene and parkinsonism. Lancet Neurol 11: 986-998.
161. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. (2009a). Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 361: 1651-1661.
162. Sidransky E, Samaddar T, Tayebi N, (2009b). Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 73: 1424-1425.
163. Silvestri L, Caputo V, Bellacchio E, Atorino L, Dallapiccola B, Valente EM, et al. (2005). Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet 14: 3477-3492.
164. Slaugenhaupt SA, (2002). The molecular basis of mucolipidosis type IV. Curr Mol Med 2: 445-450.
165. Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C, Gindi R, et al. (2009). Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J Neurosci 29: 13578-13588.
166. Sun Y, Grabowski GA, (2010). Impaired autophagosomes and lysosomes in neuronopathic Gaucher disease. Autophagy 6: 648-649.
167. Suzuki K, (1991). Neuropathology of late onset gangliosidoses. A review. Dev Neurosci 13: 205-210.
168. Suzuki Y, Oshima A, (1993). A beta-galactosidase gene mutation identified in both Morquio B disease and infantile GM1 gangliosidosis. Hum Genet 91: 407.
169. Suzuki Y, Nakamura N, Fukuoka K, (1978). GM1-gangliosidosis: accumulation of ganglioside GM1 in cultured skin fibroblasts and correlation with clinical types. Hum Genet 43: 127-131.
170. Takamura A, Higaki K, Kajimaki K, Otsuka S, Ninomiya H, Matsuda J, et al. (2008). Enhanced autophagy and mitochondrial aberrations in murine G(M1)-gangliosidosis. Biochem Biophys Res Commun 367: 616-622.
171. Tayebi N, Callahan M, Madike V, Stubblefield BK, Orvisky E, Krasnewich D, et al. (2001). Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 73: 313-321.
172. Terlecky SR, Chiang HL, Olson TS, Dice JF, (1992). Protein and peptide binding and stimulation of in vitro lysosomal proteolysis by the 73-kDa heat shock cognate protein. J Biol Chem 267: 9202-9209.
173. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, et al. (2004). Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304: 1158-1160.
174. Waddington SN, Kramer MG, Hernandez-Alcoceba R, Buckley SM, Themis M, Coutelle C, et al. (2005). In utero gene therapy: current challenges and perspectives. Mol Ther 11: 661-676.
175. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, et al. (2005). Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 102: 16842-16847.
176. Westbroek W, Gustafson AM, Sidransky E, (2011). Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol Med 17: 485-493.
177. Wisniewski KE, Zhong N, Philippart M, (2001). Pheno/genotypic correlations of neuronal ceroid lipofuscinoses. Neurology 57: 576-581.
178. Wong K, Sidransky E, Verma A, Mixon T, Sandberg GD, Wakefield LK, et al. (2004). Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 82: 192-207.
179. Xie Z, Klionsky DJ, (2007). Autophagosome formation: core machinery and adaptations. Nat Cell Biol 9: 1102-1109.
180. Xilouri M, Stefanis L, (2011). Autophagic pathways in Parkinson disease and related disorders. Expert Rev Mol Med 13: e8.
181. Zimran A, Gelbart T, Westwood B, Grabowski GA, Beutler E, (1991). High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews. Am J Hum Genet 49: 855-859.
182. Zimran A, Pastores GM, Tylki-Szymanska A, Hughes DA, Elstein D, Mardach R, et al. (2013). Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. Am J Hematol 88: 172-178.